Skip to main content
Marcel Nijland
dr.

I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.

Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
Published in: BMC Cancer
Access to document 10.1186/s12885-024-12191-z document
BACKGROUND: Primary central nervous system lymphoma (PCNSL) are rare mature B-cell lymphoproliferative diseases characterized by a high incidence of MYD88 L265P and CD79B Y196 hotspot mutations. Diagnosis of PCNSL can be challenging. The aim of the study was to analyze the detection rate of the MYD88 L265P and CD79B Y196 mutation in cell free DNA (cfDNA) in plasma of patients with PCNSL. METHODS: We analyzed by digital droplet PCR (ddPCR) to determine presence of the MYD88 L265P and CD79B Y196 hotspot mutations in cfDNA isolated from plasma of...
Yujie Zhong, Geok Wee Tan, Johanna Bult, Nick Veltmaat, Wouter Plattel, Joost Kluiver, Roelien Enting, Arjan Diepstra, Anke van den Berg, Marcel Nijland
Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands
Published in: Haematologica
Access to document 10.3324/haematol.2023.283174 document
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of mature T-cell neoplasms with an unfavorable prognosis; presentation with stage I(E) disease is uncommon. In clinical practice, an abbreviated chemotherapy treatment regimen combined with radiotherapy (combined modality treatment (CMT)) is commonly used, although evidence from clinical trials is lacking. The aim of this nationwide population-based cohort study is to describe first-line treatment and outcome of patients with stage I(E) PTCL. All newly diagnosed patients ≥ 18 years with stage I(E) anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL)...
Frederik O Meeuwes, Mirian Brink, Wouter Plattel, Marjolein W M Van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Karen J Neelis, Anne P G Crijns, Laurien A Daniëls, Tjeerd J F Snijders, Joost S P Vermaat, Gerwin A Huls, Marcel Nijland
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
Published in: Blood cancer journal
Access to document 10.1038/s41408-023-00971-y document
MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III–IV diffuse large B-cell lymphoma (DLBCL), but their impact in limited stage (LS) I–II is unclear. Therefore, we assessed the impact of MYC-R on progression-free survival (PFS) and overall survival (OS) in LS DLBCL patients at the population level. We identified 1,434 LS DLBCL patients with known MYC-R status diagnosed between 2014 and 2020, who received R-CHOP(-like) regimens using the Netherlands Cancer Registry, with survival follow-up until February 2022. Stage I patients with (n =...
A. V. de Jonge, J. A.A. Bult, D. F.E. Karssing, M. Nijland, M. E.D. Chamuleau, M. Brink
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Published in: The Lancet Haematology
Access to document 10.1016/S2352-3026(23)00279-X document
Background: Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-IVAC or with lower-intensity regimens such as DA-EPOCH-R. The aim of this study was to make a formal comparison between these regimens. Methods: This multicentre, phase 3, open-label, randomised study was done in 26 clinical centres in the Netherlands, Belgium, and Switzerland. Eligible patients were aged 18–75 years with newly diagnosed high-risk Burkitt lymphoma without CNS involvement. Patients were randomly assigned to two cycles of R-CODOX-M/R-IVAC (R-CODOX-M: rituximab 375 mg/m2 on day...
Martine E.D. Chamuleau, Frank Stenner, Dana A. Chitu, Urban Novak, Monique C. Minnema, Paul Geerts, Wendy B.C. Stevens, Thorsten Zenz, Gustaaf W. van Imhoff, Ka Lung Wu, Astrid M.P. Demandt, Marie Jose Kersten, Wim E. Terpstra, Lidwine W. Tick, Dries Deeren, Eric Van Den Neste, Michael Gregor, Hendrik Veelken, Lara H. Böhmer, Clemens B. CasparPim Mutsaers, Jeannine M. Refos, Robby Sewsaran, Liping Fu, Rianne L. Seefat, Carin A. Uyl-de Groot, Stefan Dirnhofer, Michiel Van Den Brand, Daphne de Jong, Marcel Nijland, Pieternella Lugtenburg
R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study
Published in: American Journal of Hematology
Access to document 10.1002/ajh.27151 document
For elderly frail patients with diffuse large B-cell lymphoma (DLBCL), an attenuated chemo-immunotherapy strategy of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-miniCHOP) was introduced as a treatment option as from 2014 onward in the Netherlands. Although R-miniCHOP is more tolerable, reduction of chemotherapy could negatively affect survival compared to R-CHOP. The aim of this analysis was to assess survival of patients treated with R-miniCHOP compared to R-CHOP. DLBCL patients ≥65 years, newly diagnosed in 2014-2020, who received ≥1 cycle of R-miniCHOP or R-CHOP were identified in the Netherlands Cancer Registry,...
D Al-Sarayfi, M Brink, M E D Chamuleau, R Brouwer, R S van Rijn, D Issa, W Deenik, G Huls, R Mous, J S P Vermaat, A Diepstra, J M Zijlstra, T van Meerten, M Nijland